Long-term Follow-up Study of Patients Receiving CAR-T Cells

ConditionsChronic Lymphocytic Leukemia Lymphomas Non-Hodgkin's B-Cell Lymphoma, Small Lymphocytic Mantle Cell Lymphoma Central Nervous System Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Burkitt Lymphoma Multiple Myeloma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-80

SponsorMedical College of Wisconsin

About this trial

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:

Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Eligibility criteria

Qualifiers

All participants who enrolled in a CAR-T study at Froedtert Hospital & the Medical College of Wisconsin.

Disqualifiers

There are no exclusion criteria for this study.

Trial design

Treatments tested in this trial

Long-Term Follow-Up of Participants who Received CAR-T cells

Treatment groups

500 Participants

are divided into 1 treatment group

Locations

Froedtert Hospital & Medical College of Wisconsin53226, MilwaukeeWisconsin, United States

Sponsors and collaborators

Medical College of Wisconsin

Lead sponsor

Source ClinicalTrials.gov